Biotech activity dominates as private markets embrace healthcare

Divided by asset class, Alternatives Watch tracked a total of roughly $1.8 billion in deals publicly announced in the five-day period for the week ending Jan. 6.

Private equity: $1.5 billion

• Triwise Capita led $25 million Series B extension financing round for Immune-Onc Therapeutics, a clinical-stage cancer immunotherapy company developing novel biotherapeutics targeting myeloid checkpoints. Proxima Ventures is among the investors.
• The Column Group led a $100 million Series C financing round for Synthekine Inc., a biotech company.
• Delos . . .
  

  Continue Reading

  Unlock this article instantly, along with the rest of our premium content and benefits including daily/weekly/monthly newsletters.

  Monthly

  $30

  A pay-as-you-go plan to get you started

  → Instantly unlock all new and archived articles

  → Daily, weekly and monthly e-mail newsletters

  → Access to the weekly AW Deal Watch by AW Research

  Join Now

  Annual

  $300

  Required for access to AW Research

  Get more for less - 20% discount over monthly

  → Everything in Monthly PLUS:

  → Access to articles and data from AW Research

  → AW Annual Investor Compendium – our comprehensive guide to investor activity, with a ranking of the most active investors for the year and profiles of the top global allocators

  Join Now
  Tags: Battery VenturesBiotechFossil fuelsInsurtechLife SciencesLogistics/Supply ChainM VenturesMadison Dearborn PartnersMedtechMusic RightsNovo HoldingsSoftwareSound Point Capital ManagementTechThe Vistria GroupVersant VenturesViking Global Investors